The Impact of the Genetic Polymorphism in DNA Repair Pathways on Increased Risk of Glioblastoma Multiforme in the Arab Jordanian Population: A Case-Control Study.

Arab population DNA repair genes SNP glioblastoma multiforme overall survival

Journal

The application of clinical genetics
ISSN: 1178-704X
Titre abrégé: Appl Clin Genet
Pays: New Zealand
ID NLM: 101579789

Informations de publication

Date de publication:
2020
Historique:
received: 09 02 2020
accepted: 22 05 2020
entrez: 2 7 2020
pubmed: 2 7 2020
medline: 2 7 2020
Statut: epublish

Résumé

Among the Jordanian population, brain tumors are the tenth most common type of cancers in both males and females, comprising 2.8% of all newly diagnosed neoplasms. Diffuse gliomas are the most prevalent and the most aggressive primary brain tumors in adults. The incidence of diffuse gliomas varies among different populations; this variation is partially linked to genetic polymorphisms. The purpose of the study is to examine the association between (BRCA1 rs799917G>A, rs1799966T>C, EXO1 rs1047840G>A, EME1 rs12450550T>C, ERCC2 rs13181T>G, rs1799793C>T, and XRCC1 rs1799782G>A) DNA repair gene polymorphisms and glioblastoma multiforme (GBM) susceptibility, and survival in the Jordanian Arab population. Eighty-four patients diagnosed with glioblastoma multiforme at the King Abdullah University Hospital (KAUH) between 2013 and 2018 and 225 healthy cancer-free control subjects with similar geographic and ethnic backgrounds to the patients were included in the study. Genomic DNA was extracted from the formalin-fixed paraffin-embedded tissues of the subjects. The Sequenom MassARRAY This study is the first to address the relationship between BRCA1 rs1799966 and rs799917 SNP, and the risk of GBM among the Arab Jordanian population. The findings of the study show that BRCA1 rs799917 is associated with decreased risk of GBM in the recessive model (AA vs G/G-A/G: OR, 0.46, 95% CI, 0.26-0.82, p=0.01) and the same SNP is associated with increased risk of GBM in the overdominant model (AG vs G/G-A/A: OR, 1.72, 95% CI, 1.02-2.89, p=0.04).

Identifiants

pubmed: 32606887
doi: 10.2147/TACG.S248994
pii: 248994
pmc: PMC7295542
doi:

Types de publication

Journal Article

Langues

eng

Pagination

115-126

Informations de copyright

© 2020 Al-Khatib et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Références

Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30
pubmed: 12496039
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1368-73
pubmed: 18559551
Science. 2001 Feb 16;291(5507):1284-9
pubmed: 11181991
Nat Genet. 2001 Mar;27(3):247-54
pubmed: 11242102
N Engl J Med. 2001 Jan 11;344(2):114-23
pubmed: 11150363
Neuro Oncol. 2016 Mar;18(3):388-400
pubmed: 26354927
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Cell Biochem Biophys. 2001;35(2):141-70
pubmed: 11892789
J Neurosurg. 1998 Jan;88(1):1-10
pubmed: 9420066
BMC Cancer. 2007 Aug 06;7:152
pubmed: 17683622
Trends Genet. 2000 Jun;16(6):259-64
pubmed: 10827453
Carcinogenesis. 2013 Oct;34(10):2309-13
pubmed: 23749772
J Biol Chem. 2003 Jul 4;278(27):25172-8
pubmed: 12721304
Br J Cancer. 2015 Feb 17;112(4):688-92
pubmed: 25602962
Cell. 2001 Nov 16;107(4):537-48
pubmed: 11719193
Nat Genet. 1998 Oct;20(2):184-8
pubmed: 9771713
Nat Rev Cancer. 2001 Oct;1(1):22-33
pubmed: 11900249
Acta Neuropathol. 2016 Oct;132(4):625-34
pubmed: 27573687
Mol Cell Biol. 2002 Apr;22(8):2556-63
pubmed: 11909950
PLoS One. 2016 May 02;11(5):e0154347
pubmed: 27135830
J Cell Physiol. 2001 May;187(2):145-54
pubmed: 11267994
Clin Cancer Res. 2007 Dec 15;13(24):7413-20
pubmed: 18094425
PLoS One. 2013 Sep 11;8(9):e73332
pubmed: 24039914
Nature. 2007 Jun 21;447(7147):941-50
pubmed: 17581577
Front Genet. 2012 Oct 12;3:203
pubmed: 23091480
Cancer Res. 2010 Apr 1;70(7):2789-98
pubmed: 20332227
Hum Mol Genet. 2004 Oct 15;13(20):2443-9
pubmed: 15317748
Neuro Oncol. 2011 Dec;13(12):1370-8
pubmed: 21980160
Nucleic Acids Res. 1998 Aug 15;26(16):3762-8
pubmed: 9685493
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Cancer Res. 1998 Oct 15;58(20):4537-42
pubmed: 9788596
J Clin Oncol. 2008 Dec 20;26(36):5972-9
pubmed: 19018088
Hum Mol Genet. 1994 Oct;3(10):1783-8
pubmed: 7849702
J Neurooncol. 2009 Dec;95(3):401-411
pubmed: 19562257
Br J Cancer. 2014 Nov 11;111(10):2024-32
pubmed: 25314060
Microbiol Mol Biol Rev. 2008 Dec;72(4):686-727
pubmed: 19052325
Genes Dev. 2000 Apr 15;14(8):927-39
pubmed: 10783165
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:166-71
pubmed: 16515585
Neuro Oncol. 2017 Feb 1;19(2):270-280
pubmed: 27571887
Neuro Oncol. 2014 Jun;16(6):807-14
pubmed: 24500421
Cancer Sci. 2010 May;101(5):1247-54
pubmed: 20331623
Science. 1994 Oct 7;266(5182):66-71
pubmed: 7545954
Oncotarget. 2018 Jan 6;9(9):8681-8694
pubmed: 29492227
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
J Med Biochem. 2019 Mar 01;38(1):13-21
pubmed: 30820179

Auteurs

Sohaib M Al-Khatib (SM)

Department of Pathology and Laboratory Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Nour Abdo (N)

Department of Public Health, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Laith N Al-Eitan (LN)

Department of Biotechnology and Genetic Engineering, Faculty of Science and Arts, Jordan University of Science and Technology, Irbid, Jordan.

Abdel-Hameed W Al-Mistarehi (AW)

Department of Family Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Deeb Jamil Zahran (DJ)

Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Marwan Al Ajlouni (M)

Department of Public Health, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Tariq Zuheir Kewan (TZ)

Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Classifications MeSH